DFTX Definium Therapeutics, Inc.

NASDAQ
$39.28

Definium Therapeutics, Inc. (DFTX) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal In line Selling ran in line with DFTX's own trailing one-year pace, with 100% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 5 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
5
15 transactions
Purchases
$0
0 shares
Sales
$5.1M
207,751 shares
Net activity
-$5.1M
purchases less sales

How much of that selling was preplanned? 100% planned / 0% discretionary

10b5-1 plan sales $5.1M 15 transactions · 207,751 shares
Discretionary sales $0 0 transactions · 0 shares

Largest single sale: $1.3M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Barrow Robert Chief Executive Officer Sell 10b5-1 19,023 $37.94 $721.7K 1,494,640 −1.3% of holding
Barrow Robert Chief Executive Officer Sell 10b5-1 29,208 $45.03 $1.3M 1,098,246 −2.6% of holding
Sullivan Mark Chief Legal Officer Sell 10b5-1 13,008 $45.03 $585.8K 320,571 −3.9% of holding
Karlin Daniel Chief Medical Officer Sell 10b5-1 10,035 $45.03 $451.9K 503,282 −2% of holding
Roberts Brandi Chief Financial Officer Sell 10b5-1 3,013 $45.03 $135.7K 209,487 −1.4% of holding
Wiley Matthew T. Chief Commercial Officer Sell 10b5-1 2,867 $45.03 $129.1K 174,633 −1.6% of holding
Barrow Robert Chief Executive Officer Sell 10b5-1 24,431 $18.47 $451.2K 752,454 −3.1% of holding
Sullivan Mark Chief Legal Officer Sell 10b5-1 10,702 $18.47 $197.7K 271,079 −3.8% of holding
Karlin Daniel Chief Medical Officer Sell 10b5-1 8,018 $18.47 $148.1K 413,317 −1.9% of holding
Barrow Robert Chief Executive Officer Sell 10b5-1 25,791 $13.15 $339.1K 778,477 −3.2% of holding
Sullivan Mark Chief Legal Officer Sell 10b5-1 11,276 $13.15 $148.2K 282,576 −3.8% of holding
Karlin Daniel Chief Medical Officer Sell 10b5-1 5,600 $13.15 $73.6K 425,025 −1.3% of holding
Barrow Robert Chief Executive Officer Sell 10b5-1 25,797 $9.77 $252.0K 804,268 −3.1% of holding
Sullivan Mark Chief Legal Officer Sell 10b5-1 11,278 $9.77 $110.2K 293,852 −3.7% of holding
Karlin Daniel Chief Medical Officer Sell 10b5-1 7,704 $9.77 $75.3K 430,625 −1.8% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.